Read by QxMD icon Read

Dyslipidemia drugs

Saul Flores-Unzueta, Martha Sosa-Macias, Laurence A Marchat, Ismael Lares-Assef, Omar Carrasco-Ortega, Miguel Correa-Ramirez, Fernando Guerrero-Romero, Carlos Galaviz-Hernandez
Background Simvastatin is a widely used drug for dyslipidemia treatment, and the best therapeutic effects are achieved at night time. Simvastatin administration has been associated with the development of myopathy. Some polymorphisms in genes that are involved in the metabolism and transport of simvastatin seem to have an important role in the development of simvastatin-associated myopathy. The administration of 40 mg of simvastatin to 19 hyperlipidemic subjects with regular sleep rhythms (RR) and shift workers (SW) with predominant evening rhythms and sleep-wake disturbances, uncovered two SW volunteers who developed myopathy...
August 11, 2018: Drug Metabolism and Personalized Therapy
Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Eiichi Araki, Hideki Suganami, Shun Ishibashi
BACKGROUND: Cardiovascular risk is negatively correlated with cholesterol efflux capacity (CEC) from macrophages to high-density lipoproteins (HDLs) and positively correlated with fasting and nonfasting triglyceride-rich lipoproteins (TRLs). Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator, robustly decreases the fasting TRL level, increases the HDL cholesterol (HDL-C) level, and improves the atherogenic lipoprotein subclass profile, with an adverse event rate comparable to that of placebo treatment in previous clinical studies...
June 26, 2018: Journal of Clinical Lipidology
A Rohini, Neeraj Agrawal, Harish Kumar, Virendra Nath, Vipin Kumar
The increased prevalence of cardio-metabolic disorders worldwide prompted the exploration of new strategies for its treatment. Peroxisome Proliferator activated receptor (PPAR) play major role in regulation of lipid as well as glucose metabolism and thus, natural PPARγ activators seem to be drug of choice. AIMS: In the present work, we studied norbixin which is a natural apocarotenoid derivative for its agonistic activity for PPAR γ followed by in vivo studies for amelioration of cardio-metabolic syndrome (CMetS)...
August 1, 2018: Life Sciences
Massimiliano Cazzaniga, Bernardo Bonanni
The association between obesity/overweight and carcinogenesis is a recognized highly complex and still partially unknown process. Nevertheless, these conditions are frequently related with several pathological states such as chronic inflammation, presence of dyslipidemia and insulin-resistance (metabolic disorders) which are now accepted features contributing to the increased hormonal-dependent cancer risk. Breast cancer incidence and outcome is strictly related to metabolic disorders. Thus, managing these emerging risk factors, should be a new and optimal strategy in breast cancer prevention and therapy...
August 2018: Anticancer Research
Ryoma Kayano, Yoichi Morofuji, Shinsuke Nakagawa, Shuji Fukuda, Daisuke Watanabe, Hiroki Ozawa, Masami Niwa, Takayuki Matsuo
BACKGROUND: Blood-brain barrier (BBB) disruptions are a key feature of hyperglycemia (HG)-induced cerebral damage. Patients with diabetes mellitus often have other cerebrovascular disease risk factors including hypertension, dyslipidemia, arrhythmia, and atherosclerosis obliterans. However, whether the drugs for these comorbidities are effective for improving HG-induced BBB damage is unclear. METHODS: We investigated the effect of pitavastatin, candesartan, cilostazol, propranolol, and eicosapentaenoic acid on HG-induced BBB damage...
July 27, 2018: Biochemical and Biophysical Research Communications
Fan Hong, Pengfei Xu, Yonggong Zhai
Peroxisome proliferator-activated receptors (PPARs) are a well-known pharmacological target for the treatment of multiple diseases, including diabetes mellitus, dyslipidemia, cardiovascular diseases and even primary biliary cholangitis, gout, cancer, Alzheimer's disease and ulcerative colitis. The three PPAR isoforms (α, β/δ and γ) have emerged as integrators of glucose and lipid metabolic signaling networks. Typically, PPARα is activated by fibrates, which are commonly used therapeutic agents in the treatment of dyslipidemia...
July 27, 2018: International Journal of Molecular Sciences
Yanwen Wang, Jeffrey A Zidichouski
Elevation of circulating levels of blood cholesterol, especially LDL cholesterol, and/or the decrease of HDL cholesterol levels have long been recognized as primary risk factors for developing atherosclerosis that leads to cardiovascular and cerebrovascular disease. Hypertriglyceridemia is an independent risk factor that is known to contribute to the development of atherosclerosis. Thus, various interventional efforts aimed at reducing hypercholesterolemia and hypertriglyceridemia have been practiced clinically for decades to reduce morbidity and mortality risk associated with deleterious cardiovascular and cerebrovascular events...
2018: Cholesterol
Juliette Raffort, Fabien Lareyre, Marc Clément, Réda Hassen-Khodja, Giulia Chinetti, Ziad Mallat
Aortic aneurysm is a life-threatening disease due to the risk of aortic rupture. The only curative treatment available relies on surgical approaches; drug-based therapies are lacking, highlighting an unmet need for clinical practice. Abdominal aortic aneurysm (AAA) is frequently associated with atherosclerosis and cardiovascular risk factors including male sex, age, smoking, hypertension and dyslipidemia. Thoracic aortic aneurysm (TAA) is more often linked to genetic disorders of the extracellular matrix and the contractile apparatus, but also share similar cardiovascular risk factors...
July 20, 2018: Cardiovascular Research
Sara Bringhen, Alberto Milan, Claudio Ferri, Ralph Wäsch, Francesca Gay, Alessandra Larocca, Marco Salvini, Evangelos Terpos, Hartmut Goldschmidt, Michele Cavo, Maria Teresa Petrucci, Heinz Ludwig, Holger W Auner, Jo Caers, Martin Gramatzki, Mario Boccadoro, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt
Cardiovascular disease in myeloma patients may derive from factors unrelated to the disease (age, diabetes, dyslipidemia, obesity, prior cardiovascular diseases), related to the disease (cardiac AL-amyloidosis, hyperviscosity, high-output failure, arteriovenous shunting, anemia, renal dysfunction) and linked to antimyeloma treatment (anthracyclines, corticosteroids, alkylating agents, immunomodulatory drugs, proteasome inhibitors). An accurate knowledge of cardiovascular events, effective dose reductions, prevention and management of early and late cardiovascular side effects of chemotherapeutic agents are essential in current clinical practice...
July 26, 2018: Haematologica
Valeria Luzzi, Marco Brunori, Sergio Terranova, Carlo Di Paolo, Gaetano Ierardo, Iole Vozza, Antonella Polimeni
BACKGROUND: Obstructive sleep apnea syndrome and is characterized by recurrent episodes of partial or complete upper airway collapse during sleep with consequent oxygen desaturations and cardiovascular, neurological, and metabolic impairment. CLINICAL PRESENTATION: The authors report the case of a 66-year-old male presenting "metabolic syndrome" (obesity, impaired glucose tolerance, dyslipidemia, multi-drug treated arterial hypertension), atopy, mouth breathing due to turbinate hypertrophy, and pathological daytime sleepiness...
July 26, 2018: Cranio: the Journal of Craniomandibular Practice
Yoshimi Numao, Shinya Suzuki, Hiroto Kano, Junji Yajima, Yuji Oikawa, Shunsuke Matsuno, Takuto Arita, Naoharu Yagi, Hiroaki Semba, Yuko Kato, Takayuki Otsuka, Tokuhisa Uejima, Takeshi Yamashita
Despite the increasing incidence of acute coronary syndrome (ACS) in Japan, its prognosis has improved. However, there is a paucity of longitudinal registry data providing trends of in-hospital care and prognosis of ACS in Japan. ACS patients undergoing percutaneous coronary intervention (PCI) included in the Shinken Database 2004-2014 were divided into two groups according to admission year (2004-2009, n = 390; 2010-2014, n = 328). Patient characteristics, lesion/procedure characteristics, medications at discharge, all-cause mortality, cardiovascular death, acute myocardial infarction (AMI), target lesion revascularization (TLR), re-PCI to new lesion, and coronary artery bypass graft (CABG) within 2 years after discharge were compared between the groups...
July 24, 2018: Heart and Vessels
Marta A Kowalik, Amedeo Columbano, Andrea Perra
The signaling pathways activated by thyroid hormone receptors (THR) are of fundamental importance for organogenesis, growth and differentiation, and significantly influence energy metabolism, lipid utilization and glucose homeostasis. Pharmacological control of these pathways would likely impact the treatment of several human diseases characterized by altered metabolism, growth or differentiation. Not surprisingly, biomedical research has been trying for the past decades to pharmacologically target the 3,5,3'-triiodothyronine (T3)/THR axis...
2018: Frontiers in Endocrinology
Ippei Kanazawa, Toshitsugu Sugimoto
PURPOSE: Hypertension is a risk factor of atherosclerotic diseases. However, the importance of prehypertension in Japanese patients with type 2 diabetes mellitus (T2DM) is controversial. The aim of this study was to examine association between prehypertension, hypertension and atherosclerosis in T2DM. METHODS: We recruited 179 Japanese patients with T2DM, who never took any medication for diabetes, hypertension, dyslipidemia, or atherosclerosis. Intima-media thickness (IMT) of common carotid artery was evaluated by high-resolution B-mode ultrasonography...
2018: PloS One
Samuel Treviño, Alfonso Díaz, Eduardo Sánchez-Lara, Víctor Enrique Sarmiento-Ortega, José Ángel Flores-Hernández, Eduardo Brambila, Francisco J Meléndez, Enrique González-Vergara
Vanadium(IV/V) compounds have been studied as possible metallopharmaceutical drugs against diabetes mellitus. However, mechanisms of action and toxicological threshold have been tackled poorly so far. In this paper, our purposes were to evaluate the metabolic activity on dyslipidemia and dysglycemia, insulin signaling in liver and adipose tissue, and toxicology of the title compound. To do so, the previously reported bisammonium tetrakis 4-( N , N -dimethylamino)pyridinium decavanadate, the formula of which is [DMAPH]4 (NH4 )2 [V10 O28 ]·8H2 O (where DMAPH is 4-dimethylaminopyridinium ion), was synthesized, and its dose-response curve on hyperglycemic rats was evaluated...
2018: Bioinorganic Chemistry and Applications
Subrata Deb, Prasanth Puthanveetil, Prashant Sakharkar
Background: To examine the association between low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels and liver enzyme functions. Methods: The National Health and Nutrition Examination Survey (NHANES) data from 1999 to 2012 was used to examine the association between liver enzymes and lipid levels amongst adults in the United States. Results: Sixteen percent adults had ALT > 40 U/L, 11% had AST > 40 U/L, and 96% had ALP > 120 U/L...
2018: International Journal of Hepatology
Cene Skubic, Živa Drakulić, Damjana Rozman
Nonalcoholic fatty liver disease (NAFLD) is the most frequent liver disease in the world. It describes a term for a group of hepatic diseases including steatosis, fibrosis, and cirrhosis that can finally lead to hepatocellular carcinoma. There are many factors influencing NAFLD initiation and progression, such as obesity, dyslipidemia, insulin resistance, genetic factors, and hormonal changes. However, there is also lean-NAFLD which is not associated with obesity. NAFLD is considered to be a sexually dimorphic disease...
July 3, 2018: Expert Opinion on Drug Metabolism & Toxicology
Mariël F van Stee, Albert A de Graaf, Albert K Groen
Patients with diabetes type 2 have an increased risk for cardiovascular disease and commonly use combination therapy consisting of the anti-diabetic drug metformin and a cholesterol-lowering statin. However, both drugs act on glucose and lipid metabolism which could lead to adverse effects when used in combination as compared to monotherapy. In this review, the proposed molecular mechanisms of action of statin and metformin therapy in patients with diabetes and dyslipidemia are critically assessed, and a hypothesis for mechanisms underlying interactions between these drugs in combination therapy is developed...
June 30, 2018: Cardiovascular Diabetology
Juan Decara, Antonia Serrano, Francisco Javier Pavón, Patricia Rivera, Rocio Arco, Ana Gavito, Antonio Vargas, Juan A Navarro, Ruben Tovar, Antonio J Lopez-Gambero, Ana Martínez, Juan Suárez, Fernando Rodríguez de Fonseca, Elena Baixeras
Chronic NP-1 administration reduces body weight and hepatic steatosis despite induction of tolerance in adiponectin gene transcription with respect to the acute actions of this drug. This study explored the hypothesis that NP-1 could exert these effects through mechanisms independent of adiponectin. To this aim, we took advantage of the Zucker (fa/fa) rat model, which exhibits obesity, fatty liver and elevated leptin and adiponectin levels. Body weight and food intake were reduced after chronic NP-1 treatment...
June 29, 2018: Scientific Reports
Jonghoon Lim, Haerim Lee, Jiwon Ahn, Jeongjun Kim, Joonseong Jang, Yonghyun Park, Birang Jeong, Heejung Yang, Soon Shik Shin, Michung Yoon
ETHNOPHARMACOLOGICAL RELEVANCE: The herbal composition Gyeongshingangjeehwan 18 (GGEx18), composed of Rheum palmatum L. (Polygonaceae), Laminaria japonica Aresch (Laminariaceae), and Ephedra sinica Stapf (Ephedraceae), is used as an antiobesity drug in Korean clinics. The constituents of GGEx18 have traditionally been reported to inhibit obesity and related metabolic diseases such as insulin resistance and dyslipidemia. OBJECTIVE: This study investigated the effects of GGEx18 on nonalcoholic fatty liver disease (NAFLD) in mice fed a high-fat diet (HFD) and the underlying cellular and molecular mechanisms involved...
June 26, 2018: Journal of Ethnopharmacology
Dhananjay Yadav, Kyung-Hyun Cho
Increasing incidences of type 2 diabetes makes it necessary to have a better understanding of the risk factors for its prediction. Taking a note of resilience in risk factors, dynamics of the emerging factors other than traditional ones are showing a great interest in recent years which imprints a significant contribution in the occurrence of diabetes. Of different factors, sleep duration was acknowledged as a most common risk factor for dyslipidemia, obesity, hypertension, metabolic syndrome and diabetes. Adhering to the state of information available, the review highlights the underlying mechanisms toward establishing the relationship between sleep duration and diabetes; compiled mainly through laboratory and epidemiological studies...
June 28, 2018: Current Drug Metabolism
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"